Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-03-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Lepu Biopharma Co., Ltd. regarding the FDA granting Fast Track Designation to their drug candidate MRG004A for pancreatic cancer treatment. It is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. The document is relatively short (2936 characters) and serves to inform shareholders and the market about this development. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on the authorised/registered share capital and issued shares of Lepu Biopharma Co., Ltd. It includes confirmations related to share issuance and compliance with listing rules on the Hong Kong Stock Exchange. The document does not contain financial statements or earnings data, nor does it announce voting results or management changes. It is a regulatory submission related to share capital and share issuance movements, fitting the description of a Major Shareholding Notification or Share Issue/Capital Change. Given the detailed nature of share capital and issued share movements, and no indication of share repurchases or director dealings, the best fit is Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement but a substantive regulatory filing on capital changes.
2024-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities, specifically focusing on share capital and issued shares for Lepu Biopharma Co., Ltd. It details authorized/registered share capital, movements in issued shares, confirmations related to securities issuance, and compliance with listing rules. The document is structured as a regulatory submission with no financial statements or earnings data, and it primarily reports on share capital and securities movements for a specific month (January 2024). This type of document aligns with a Major Shareholding Notification or Share Issue/Capital Change, but since there are no changes in share capital or issued shares (all increases/decreases are zero), it is more of a regulatory compliance report on share capital status rather than a capital raising or share issuance announcement. Given the detailed reporting on share capital and securities movements, the best fitting category is Share Issue/Capital Change (SHA), as it covers announcements regarding share capital and share movements under listing rules, even if no changes occurred this month. Confidence is high because the document matches the description of SHA filings and does not fit other categories like Annual Report, Earnings Release, or Regulatory Filings which are more general or different in content.
2024-02-05 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'Articles of Association' for Lepu Biopharma Co., Ltd., passed at an extraordinary general meeting. It contains detailed company governance rules, including chapters on general provisions, operational objectives, shares issuance and transfer, shareholders and general meetings, board of directors, senior management, supervisory committee, financial accounting system, audit, notice and announcement, merger, dissolution, and amendments to the articles. The content is a comprehensive governance document outlining the company's internal rules, board structure, shareholder rights, and management organization. It is not a financial report, earnings release, or announcement of voting results. It is a governance document detailing the company's internal rules and governance practices, fitting the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text, not a brief announcement or summary.
2024-01-31 English
List of Directors and their Roles and Functions
Board/Management Information Classification · 95% confidence The document is a list of directors and their roles and functions on the board and its committees. It does not contain financial data, audit results, or meeting minutes. It is an announcement related to the composition and structure of the company's board of directors and their committee memberships. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on board membership, confirming it is not a full report or presentation.
2024-01-31 English
(1) POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024&#x3b; (2) RE-ELECTION OF DIRECTORS AND SUPERVISORS&#x3b; (3) CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR&#x3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results of an Extraordinary General Meeting (EGM) held on January 31, 2024. It details the re-election of directors and supervisors, changes in employee representative supervisor, and amendments to the Articles of Association. The document includes voting results and biographical details of the re-elected directors and supervisors. It is not a full annual report, audit report, or financial statement, but rather an official announcement of shareholder voting outcomes and board changes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting results, confirming it is not merely a brief notice or report publication announcement. Therefore, the appropriate classification is DVA with high confidence.
2024-01-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.